Evotec to Report First Quarter Results on 10 May 2012

        Print
| Source: Evotec AG

HAMBURG, Germany, May 4, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) will report its financial results for the first quarter of 2012 on Thursday, 10 May 2012.

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance:

Conference call details:

Date: Thursday, 10 May 2012
Time:
09.30 a.m. CEST
08.30 a.m. BST
03.30 a.m. US time (East Coast)
 
From Europe:
+49-(0)-6103-485-3001 (Germany)
+44-207-153-2027 (UK)
From the US: +1-480-629-9822
 
Access Code: 4534463

A simultaneous slide presentation for participants dialing in via phone is available at www.equitystory.com, password: evotec0512.

Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49 69 58 99 90 567 (Germany) or +44 207 959 6720 (UK) and in the US by dialing +1 303 590 3030. The access code is 4534463#. The on-demand version of the webcast will be available on our website:

http://www.evotec.com /Investors/Financial-Reports-2010-2012

About Evotec AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Dr Werner Lanthaler
Chief Executive Officer
+49.(0)40.560 81-242
+49.(0)40.560 81-333 Fax


Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Deutschland)